To verify the performance of UDS in the detection of ITD mutations in clinical AML samples, we performed parallel UDS and conventional analyses on 20 AML samples from patients enrolled in an experimental clinical trial (AMBIT FLT3 inhibitor AC220–002). This evidence concerns the gene FLT3 and acute myeloid leukemia.